DetermaIO Publications and Abstracts
Publications
Iwase T, Blenman KRM, Li X, Reisenbichler E, Seitz RS, Hout DR, Nielsen TJ, at al. (2021) A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers 13(19), 4839 – View Article
Nielsen TJ, Ring BZ, Seitz RS, Hout DR, Schweitzer BL. (2021) A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon Open 3:e06438 – View Article
Ranganath, H., Jain, A. L., Smith, J. R., Ryder, J., Chaudry, A., Miller, E., Hare, F., Valasareddy, P., Seitz, R. S., Hout, D. R., Varga, M. G., Schweitzer, B. L., Nielsen, T. J., Mullins, J., Ross, D. T., Gandara, D. R., & Vidal, G. A. (2022). Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC cancer, 22(1), 407. https://doi.org/10.1186/s12885-022-09470-y – View Article
Spring, L. M., Bar, Y., & Isakoff, S. J. (2022). The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer, Journal of the National Comprehensive Cancer Network, 20(6), 723-734. – View Article
Saltman D.L., Nielsen T.J., Salina D., Hout D.R., McMahon F.B., Valev B.R., Huk M., Chandra P.K., Spille J., Seitz R.S., Schweitzer B.L. (2021). Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single[1]agent pembrolizumab. Ther Adv Med Oncol. Apr 19;18. – View Article
Posters & Abstracts
Boccaccino A, Seitz R, Giordano M, Rossini D, et al. (2022). An immune-related gene expression profile to predict the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study. J Clin Oncol 40, 2022 (suppl 16; abstr 3581)
Nielsen TJ, Seitz RS, Varga MG, Cronister CT, et al. (2022). Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs). Cancer Res (2022) 82 (12_Supplement): 1272.
Page D, Collins KL, Rajamanickam V, Moxon N, et al. (2022). Association of 27-gene IO score with outcome in a phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 40, 2022 (suppl 16; abstr 1082)
Sharma P, Stecklein SR, Yoder R, Staley JM, et al. (2022). Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). J Clin Oncol 40, 2022 (suppl 16; abstr 513)
Varga MG, Cronister C, Nielsen TJ, Ross DT, et al. (2022). The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer. J Clin Oncol 40, 2022 (suppl 16; abstr 4058)
Bianchini G, Dugo M, Huang C, Egle D, Bermejo B, Seitz RS, Nielsen TJJ. (2021) LBA12 – Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial. Abstract presented at the European Society for Medical Oncology Meeting. – View Abstract
Dugo M, Huang C, Egle D, Begona B, et al. (2021). Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial. 2021 San Antonio Breast Cancer Symposium. Abstract ID: #1270.
Nielsen T, Varga M, McGregor K, Ross D, et al. (2021). CD274 (PD-L1) gene expression and the 27-gene immuno-oncology (IO) assay are associated with efficacy to immune checkpoint inhibitor treated patients with non-small cell lung cancer. Society for Immunotherapy of Cancer (SITC) Annual Meeting. Abstract ID: #5
Seitz RS, Nielsen TJ, Schweitzer BL, Gandara DR, Parikh M, Ross DT. (2021) Association with immune checkpoint inhibitor efficacy of a 27-gene classifier in renal cell cancer. Poster presented at the American Society of Clinical Oncology Annual Meeting.
View Abstract | View Poster | View Video of Explanation
Seitz RS, Ross DT, Nielsen TJ, Hout DR, Schweitzer BL. (2021) Validation of a 27-gene immuno-oncology algorithm in metastatic urothelial carcinoma treated with an immune checkpoint inhibitor. Presented at the American Association for Cancer Research Annual Meeting.
View Abstract | View Poster | View Video of Presentation
Seitz RS, Nielsen TJ, Schweitzer BL, Hout DR, Ross DT. (2021) Pathway modeling to translate the 27-gene immuno-oncology algorithm into bladder cancer. Poster presented at the American Association for Cancer Research Annual Meeting.
View Abstract | View Poster | View Video of Explanation
Varga M, Nielsen T, Vidal G, Hout R, et al. (2021, September). A 27-gene IO assay to capture the tumor immune microenvironment is associated with response in metastatic and primary tumors. 2021 World Conference on Lung Cancer. Abstract ID: #839.
View Poster
Iwase T, Pusztai L, Blenman K, Li X, Seitz R, et al. (2020, May). Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. Journal of Clinical Oncology. 38 supplement: abstr 3117.
Nielsen, TJ, McMahon FB, Spille J, Hout DR, Dickenson K, et al. (2020) Tissue Requirements of a Novel 27-Gene Immuno-Oncology Algorithm Measuring Tumor Microenvironment to Predict Response to Immunotherapies. Poster Presented at the Association for Molecular Pathology Annual Meeting & Expo
View Abstract | View Poster
Nielsen T, Seitz R, Ross D, Hout D, Schweitzer B. (2020, November) Mesenchymal features of a novel 27-gene algorithm associate with canonical tumor promoting signaling pathways which may identify therapeutic options for immunotherapy resistant patients. Poster presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting. – View Abstract
Ranganath H, Jain A, Smith J, Ryder J, Chaudry A, et al. (2019). One-year progression-free survival in lung cancer patients treated with immune checkpoint inhibitors is significantly associated with a novel immunomodulatory signature but not PD-L1 staining. Poster presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting, National Harbor, MD. – View Abstract